Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation

IntroductionDiscontinuation of tyrosine kinase inhibitor (TKI) treatment is emerging as the main therapy goal for Chronic Myeloid Leukemia (CML) patients. The DESTINY trial showed that TKI dose reduction prior to cessation can lead to an increased number of patients achieving sustained treatment fre...

Full description

Bibliographic Details
Main Authors: Elena Karg, Christoph Baldow, Thomas Zerjatke, Richard E. Clark, Ingo Roeder, Artur C. Fassoni, Ingmar Glauche
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
chronic myeloid leukaemia (CML)
treatment free remission (TFR)
dose reduction
tyrosine kinase inhibitor (TKI)
mathematical modelling
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1028871/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1028871/full

Similar Items